Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF (MRIinfantCF)

August 21, 2017 updated by: Children's Hospital Medical Center, Cincinnati

MRI Predictors of Infection, Inflammation, and Structural Lung Damage in CF (Cystic Fibrosis)

Our research is comparing the lungs of babies and young children with CF (cystic fibrosis) to those without CF. We are looking at the blood flow in the lungs to help doctors better understand how CF damages lungs and how to prevent this damage in the future. We will use MRI (Magnetic Resonance Imaging) and special blood tests as ways to understand early changes in the lungs of babies and young children with CF. We will look at the special blood tests to see if they can work as signals for the doctors to better understand when changes are happening in the lungs.

For the babies with CF, we will compare MRI images of the lungs to their CT images (also sometimes called CAT scans or Computerized Tomography). We hope that this study will help us reduce the number of X-rays and CT scans children with CF might get in the future. Because MRI's do not use radiation, this could reduce the amount of radiation exposure that children with CF would get over their lifetime.

Study Overview

Status

Completed

Conditions

Detailed Description

Cystic fibrosis (CF) is a well characterized multi-organ disease producing mucus obstruction, chronic lung infection, inflammation, and oxidant stress. These processes result in airway damage, chronic pulmonary symptoms, and ultimately death in young adulthood. These processes are largely silent in the infant and toddler CF population, and ultimately result in lung damage and symptoms of CF. Detection and monitoring of lung disease in infants and toddlers with CF is currently limited, and is a major barrier to advancements in care and research for this population.

This study will be performed in CF and non-CF controls age 6 months - 4.5 years, with repeated measures in CF patients over this window. We intend to examine new techniques to evaluate the lung of CF infants based on magnetic resonance imaging (MRI) that incorporates measurements of lung structure and blood flow. In the CF group, we will augment MRI images with CT images to determine structural relationships between MR and CT (a gold standard to assess lung structure in CF). We will correlate imaging data with core peripheral biomarkers of CF using an unbiased, metabolomic and proteomic-based approach. It is hoped that the results of this study will provide support for the use of MRI to monitor lung structure and blood flow in early CF lung disease, potentially providing a modality to monitor disease status independent of radiation exposure.

We hypothesize that MRI of the lung and pulmonary circulation has the potential to serve as a sensitive and portable tool to monitor early CF lung disease. We will examine three functional aspects of pulmonary blood flow (total and regional pulmonary perfusion, vascular resistance, and aortopulmonary collateral blood flow) compared with structural assessment of the lung by MRI and CT.

This proposal couples advancements in magnetic resonance imaging (MRI) techniques with the emerging technologies of metabolomics and proteomics, linking new MR imaging to candidate and novel pathway analysis. We will use the new technologies (metabolomics and proteomics - performed on peripheral blood samples) to determine if altered signaling pathways detected in the blood are related to changes in the lung. We hypothesize that changes in pulmonary perfusion and/or structure can be correlated with peripheral biomarkers identified by metabolomics and proteomic methodology.

Candidate metabolomic pathways that have been shown to segregate CF from non-CF conditions (including oxidative status, purinergic signaling, and glucose metabolism) will be the focus of initial biomarker analysis, with advanced bioinformatic techniques applied to define novel relationships between the metabolome and imaging. Proteomics will serve a validating function, helping to assign enzyme pathways to metabolomics alterations.

The study design includes 30 CF subjects divided into 2 age groups (6 to 12 month old and 24 to 36 month old) who will receive chest CT and High Resolution CT (HRCT) at baseline and 12 months later. They will be compared to 30 age matched non-CF subjects who will have one visit of MRI with contrast. The non-CF group only includes subjects scheduled for MRI for clinical reasons and will have an additional chest imaging at the end of their scheduled MRI. Both groups will have blood drawn to measure metabolomic and proteomic markers.

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Cincinnati Children's Hospital Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 4 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

CF infants 6 to 12 months or CF infants 24 to 36 months or non-CF controls between 6 months to 52 months scheduled for clinical MRI and willing to have contrast.

Description

Inclusion criteria:

CF

  • Age at enrollment 6 to 12 months or 24 to 52 months.
  • Diagnosed with two CF-causing mutations ('severe' mutations, classes 1, 2, or 3).

Non-CF

  • Age at enrollment 6 months to 52 months
  • Clinically scheduled for MRI neuroimaging
  • Negative history of renal abnormalities

Exclusion criteria:

CF

  • Pulmonary exacerbation
  • Any known intracardiac defects
  • Serum creatinine > 1.5 times the upper limit of normal for age
  • Cystatin C > 0.53 (cutoff for normal range)

Non-CF

  • Active lung disease as determined by assessment of anesthesiologist
  • Any known intracardiac defects
  • Results of the most recent serum creatinine within past 12 months above normal range for age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
CF group
Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
Non-CF Control
1 chest MRI with contrast and blood for proteomics and metabolomics

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary blood flow
Time Frame: CF: Baseline and 1 year; Control: Baseline
Comparison of pulmonary blood flow will be done between MRI pair matched subjects.
CF: Baseline and 1 year; Control: Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
comparison of lung structure by MRI and CT
Time Frame: Baseline and one year
On CF cohort, comparison of CT to MRI.
Baseline and one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Children's Hospital Medical Center, Cincinnati

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: John P Clancy, MD, Cincinnati Childrens Hospital Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2013

Primary Completion (Actual)

January 9, 2017

Study Completion (Actual)

January 9, 2017

Study Registration Dates

First Submitted

April 8, 2013

First Submitted That Met QC Criteria

April 12, 2013

First Posted (Estimate)

April 16, 2013

Study Record Updates

Last Update Posted (Actual)

August 23, 2017

Last Update Submitted That Met QC Criteria

August 21, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIN001InfantMRI
  • R457-CR11_01 (Other Grant/Funding Number: CF FOUNDATION)
  • R01HL116226 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cystic Fibrosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe